Semaglutide Dosing for Weight Loss | Biomarker-Guided Approach

Last reviewed: May 31, 2026

Last updated: May 31, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide dosing for weight loss follows a stepwise escalation protocol, starting at 0.25 mg weekly and increasing to a target maintenance dose of 2.4 mg per week over approximately 16 to 20 weeks. Clinical trials demonstrate that this gradual titration minimizes gastrointestinal side effects while allowing metabolic adaptation.

Understanding your individual response profile—shaped by genetic factors, current metabolic status, and overall health—can help inform meaningful conversations with your healthcare provider about whether a standard dosing trajectory fits your unique physiology. PlexusDx supports precision-wellness approaches that go beyond one-size-fits-all protocols.

Standard Semaglutide Dosing Protocol for Weight Loss

The FDA-approved dosing escalation for semaglutide in weight management (brand name Wegovy) follows a four-week interval schedule. Week 1-4: 0.25 mg subcutaneously once weekly. Weeks 5-8: 0.5 mg weekly. Weeks 9-12: 1.0 mg weekly. Weeks 13-16: 1.7 mg weekly. Week 17 onward: 2.4 mg weekly maintenance.

This tiered approach allows your body to adapt to the medication's effects on appetite signaling and glucose metabolism. The gradual escalation reduces nausea and gastrointestinal disruption, improving treatment tolerability and adherence rates in clinical populations.

Dose Adjustment Framework: Clinical Factors and Individual Response

Not all individuals require or tolerate the standard 2.4 mg maintenance dose. Some patients achieve meaningful weight loss at 1.0 or 1.7 mg, while others may benefit from staying at an earlier step if side effects emerge. Your provider may adjust your dose based on weight loss trajectory, metabolic response, and tolerability profile.

Dosing Milestone	Typical Weekly Dose	Clinical Considerations
Initiation Phase	0.25 mg	Assess tolerability; monitor for nausea or GI effects
Early Escalation	0.5–1.0 mg	Weight loss typically becomes visible; side effects often peak then stabilize
Maintenance Threshold	1.7–2.4 mg	Individual response varies; some patients plateau at lower doses
Dose Adjustment	Variable	Provider may reduce, maintain, or pause if intolerance occurs

Genetic and Metabolic Biomarkers in Dosing Decisions

Genetic variation in the GLP-1 receptor (GLP1R) and related metabolic pathways may influence how individuals respond to semaglutide and at what dose meaningful results emerge. Variants in GLP1R rs6923761 and GIPR rs1800437 can affect receptor sensitivity and appetite regulation signaling, potentially shaping individual response trajectories.

Metabolic biomarkers including fasting glucose, HbA1c, lipid profiles, and inflammatory markers provide additional context for dosing conversations. Understanding your baseline metabolic status helps your provider anticipate whether you may benefit from incremental dose progression, maintenance at an intermediate step, or additional metabolic support.

Safety Considerations and Provider-Guided Dosing

Semaglutide is not appropriate for all patients. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe renal or hepatic impairment, and active pancreatitis. Pregnancy and breastfeeding are also exclusionary. Your healthcare provider must conduct a thorough evaluation before initiating treatment.

Dose escalation should always occur under qualified medical supervision. If gastrointestinal side effects become severe—such as persistent vomiting, abdominal pain, or signs of pancreatitis—report these to your provider immediately. They may recommend pausing the dose step or remaining at your current level while side effects resolve.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context around your individual predispositions in GLP-1 receptor and metabolic pathways. The test evaluates key variants including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—genetic markers associated with appetite regulation and weight management capacity. These insights should be interpreted with a qualified healthcare provider as part of a comprehensive evaluation.

Genetic predispositions are not deterministic. They reveal relative risk or capacity within peptide signaling pathways, not whether a specific dose will work for you. Some individuals with favorable GLP1R variants may respond robustly at lower doses, while others may require titration to standard maintenance levels. The test supports a more informed conversation, not a prediction of exact medication response.

When combined with metabolic biomarkers and clinical history, genetic context can help your healthcare provider craft a more personalized dosing strategy—one that accounts for your unique physiology rather than applying a generic protocol. PlexusDx compounded semaglutide offerings come with the ability to partner this genetic insight with clinical decision-making and flexible dosing options.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $229-$309/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.